Platforms for high-throughput screening of Wnt/Frizzled antagonists

Area of Science:

• Molecular Biology
• Cell Signaling
• Drug Discovery

Background:

• Wnt signaling pathways, mediated by Wnt lipoglycoproteins and Frizzled receptors, are vital for development and physiology.
• Dysregulated Wnt signaling is implicated in cancer progression, including carcinogenesis and metastasis.
• Targeting Wnt-Frizzled interactions is a key strategy for anti-cancer drug discovery, yet clinical progress is limited.

Purpose of the Study:

• To provide an overview of current and emerging assay platforms for screening Wnt-Frizzled antagonists.
• To identify potential reasons for delays in developing Wnt-Frizzled inhibitors, such as suboptimal assays.
• To highlight promising assay technologies for identifying effective Wnt-Frizzled blocking agents.

Main Methods:

• Review of existing literature on Wnt signaling assays.
• Analysis of emerging assay technologies for antagonist screening.
• Focus on G protein-activating assays leveraging Frizzled receptor GPCR-like properties.

Main Results:

• Several assay platforms for Wnt-Frizzled antagonist screening are available and under development.
• Suboptimal assays may contribute to the slow progress in clinical translation.
• G protein-activating assays show promise due to the recognized GPCR characteristics of Frizzled receptors.

Conclusions:

• Improved assay development is essential for advancing Wnt-Frizzled antagonist discovery.
• Novel assay platforms, particularly those utilizing Frizzled's GPCR-like functions, offer new avenues for drug screening.
• Accelerated development of Wnt-Frizzled inhibitors could lead to new cancer therapies.